Demographics of patients with B-ALL who experienced LS or lineage drift
| Characteristics . | Patients with LS, n = 70 . | Patients with LD, n = 10 . |
|---|---|---|
| Median age at initial B-ALL diagnosis, y (range) | 11.9 (0∗-76.5) | 3.4 (0†-17.1) |
| Median age at LS diagnosis, y (range) | 14.5 (0.4-77.3) | 4.2 (0.4-18.0) |
| Sex | ||
| Male (%) | 37 (52.9%) | 5 (50%) |
| Female (%) | 33 (47.1%) | 5 (50%) |
| Race | ||
| White | 48 (68.6%) | 6 (60%) |
| Black | 1 (1.4%) | 1 (10%) |
| Asian | 7 (10%) | 1 (10%) |
| Multiracial | 1 (1.4%) | 0 |
| Unknown | 13 (18.6%) | 2 (20%) |
| Ethnicity | ||
| Hispanic | 17 (24.3%) | 1 (10%) |
| Non-Hispanic | 43 (61.4%) | 8 (80%) |
| Unknown | 10 (14.3%) | 1 (10%) |
| Genotype/phenotype of original B-ALL at diagnosis‡ | ||
| KMT2Ar | 45 (64.3%) | 7 (70%) |
| CDKN2A mutation | 5 (7.1%) | 0 |
| BCR::ABL1 | 4 (5.7%) | 0 |
| TP53 mutation | 6 (8.6%) | 0 |
| ZNF384 rearrangement | 3 (4.3%) | 0 |
| CRLF2 rearrangement | 3 (4.3%) | 0 |
| PTPN11 mutation | 2 (2.9%) | 0 |
| DUX4 rearrangement | 1 (1.4%) | 0 |
| IKZF1 mutation | 1 (1.4%) | 0 |
| Complex karyotype | 10 (14.3%) | 0 |
| History of prior HSCT | 22 (31.4%) | 4 (40%) |
| Prior to most proximal immunotherapy | 15 (21.4%) | 1 (25%) |
| After most proximal immunotherapy | 7 (10%) | 3 (75%) |
| Most proximal immunotherapy prior to LS | ||
| CAR T-cells§ | 34 (48.6%) | 4 (40%) |
| Blinatumomab | 31 (44.3%) | 5 (50%) |
| Inotuzumab | 4 (5.7%) | 1 (10%) |
| CD19 antibody drug conjugate|| | 1 (1.4%) | 0 |
| Marrow disease burden at time of proximal immunotherapy | ||
| MRD-negative CR | 10 (14.3%) | 1 (10%) |
| M1 | 19 (27.1%) | 4 (40%) |
| M2 | 11 (15.7%) | 2 (20%) |
| M3 | 30 (42.9%) | 3 (30%) |
| Presence of CNS disease at time of proximal immunotherapy | 10 (14.3%) | 1 (10%) |
| Presence of non-CNS EMD at time of proximal immunotherapy | 5 (7.1%) | 1 (10%) |
| Median time to LS from most proximal immunotherapy, mo (range) | 1.5 (0¶-36.5) | 2.0 (0¶-8.0) |
| Characteristics . | Patients with LS, n = 70 . | Patients with LD, n = 10 . |
|---|---|---|
| Median age at initial B-ALL diagnosis, y (range) | 11.9 (0∗-76.5) | 3.4 (0†-17.1) |
| Median age at LS diagnosis, y (range) | 14.5 (0.4-77.3) | 4.2 (0.4-18.0) |
| Sex | ||
| Male (%) | 37 (52.9%) | 5 (50%) |
| Female (%) | 33 (47.1%) | 5 (50%) |
| Race | ||
| White | 48 (68.6%) | 6 (60%) |
| Black | 1 (1.4%) | 1 (10%) |
| Asian | 7 (10%) | 1 (10%) |
| Multiracial | 1 (1.4%) | 0 |
| Unknown | 13 (18.6%) | 2 (20%) |
| Ethnicity | ||
| Hispanic | 17 (24.3%) | 1 (10%) |
| Non-Hispanic | 43 (61.4%) | 8 (80%) |
| Unknown | 10 (14.3%) | 1 (10%) |
| Genotype/phenotype of original B-ALL at diagnosis‡ | ||
| KMT2Ar | 45 (64.3%) | 7 (70%) |
| CDKN2A mutation | 5 (7.1%) | 0 |
| BCR::ABL1 | 4 (5.7%) | 0 |
| TP53 mutation | 6 (8.6%) | 0 |
| ZNF384 rearrangement | 3 (4.3%) | 0 |
| CRLF2 rearrangement | 3 (4.3%) | 0 |
| PTPN11 mutation | 2 (2.9%) | 0 |
| DUX4 rearrangement | 1 (1.4%) | 0 |
| IKZF1 mutation | 1 (1.4%) | 0 |
| Complex karyotype | 10 (14.3%) | 0 |
| History of prior HSCT | 22 (31.4%) | 4 (40%) |
| Prior to most proximal immunotherapy | 15 (21.4%) | 1 (25%) |
| After most proximal immunotherapy | 7 (10%) | 3 (75%) |
| Most proximal immunotherapy prior to LS | ||
| CAR T-cells§ | 34 (48.6%) | 4 (40%) |
| Blinatumomab | 31 (44.3%) | 5 (50%) |
| Inotuzumab | 4 (5.7%) | 1 (10%) |
| CD19 antibody drug conjugate|| | 1 (1.4%) | 0 |
| Marrow disease burden at time of proximal immunotherapy | ||
| MRD-negative CR | 10 (14.3%) | 1 (10%) |
| M1 | 19 (27.1%) | 4 (40%) |
| M2 | 11 (15.7%) | 2 (20%) |
| M3 | 30 (42.9%) | 3 (30%) |
| Presence of CNS disease at time of proximal immunotherapy | 10 (14.3%) | 1 (10%) |
| Presence of non-CNS EMD at time of proximal immunotherapy | 5 (7.1%) | 1 (10%) |
| Median time to LS from most proximal immunotherapy, mo (range) | 1.5 (0¶-36.5) | 2.0 (0¶-8.0) |
ADC, antibody drug conjugate; LD, lineage drift; MRD, measurable residual disease.
Age, 12 days.
Age, 1 day.
LS detected during blinatumomab infusion.
At diagnosis or relapse preceding LS.
CAR T-cell constructs included in those with LS: CD19 CAR T cells in 29 (85.3%) patients, CD19/CD22 CAR T cells in 3 (8.8%), and CD22 CAR T cells in 2 (5.9%) patients.
CD19 ADC: ADCT-402.39